Heck Capital Advisors LLC Invests $60,000 in AtriCure, Inc. (NASDAQ:ATRC)

Heck Capital Advisors LLC purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the 4th quarter, HoldingsChannel reports. The firm purchased 1,955 shares of the medical device company’s stock, valued at approximately $60,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its holdings in shares of AtriCure by 151.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock valued at $6,425,000 after acquiring an additional 138,046 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in AtriCure by 31.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after purchasing an additional 119,929 shares during the period. Champlain Investment Partners LLC grew its holdings in AtriCure by 4.3% during the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock valued at $78,253,000 after purchasing an additional 115,813 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of AtriCure by 14.6% in the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock valued at $18,621,000 after purchasing an additional 84,700 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of AtriCure in the third quarter worth $1,991,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $40.00 target price on shares of AtriCure in a research note on Tuesday, December 17th. Oppenheimer lifted their price objective on AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Needham & Company LLC raised their target price on AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Finally, UBS Group upped their price target on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.38.

AtriCure Stock Performance

Shares of NASDAQ ATRC opened at $39.87 on Monday. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -48.04 and a beta of 1.42. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The business has a fifty day simple moving average of $34.72 and a 200 day simple moving average of $30.25. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.